

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
Imran AHMAD *et al.*) Group Art Unit: Unassigned
Continuation of Application No.: 09/540,050) Examiner: Unassigned
Filed: August 26, 2003) Confirmation No.: Unassigned
For: D AND L ETHERLIPID)
STEREOISOMERS AND LIPOSOMES)

FIRST
INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the attached information in conformance with 37 C.F.R. §§ 1.97 and 1.98. In accordance with 37 C.F.R. § 1.98, a copy of each of the listed documents, except those documents which were previously made of record in prior application No. 09/540,050, filed March 31, 2000, is enclosed.

Since the documents are being filed within the time period set forth in 37 C.F.R. § 1.97(b) no fee or statement is required.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner-initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: _____

Teresa Stanek Rea
Registration No. 30,427

P.O. Box 1404
Alexandria, VA 22313-1404
(703) 836-6620
Date: August 26, 2003

SHEET 1 OF 4

| | | | |
|--|--|----------------------------------|--|
| Substitute for forms 1449A/PTO & 1449B/PTO | | ATTORNEY'S DKT NO. 033388-566 | CONTINUATION OF APPLICATION NO. 09/540,050 |
| FIRST INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | APPLICANT Imran AHMAD et al | |
| | | FILING DATE August 26, 2003 | GROUP Unassigned |

| U.S. PATENT DOCUMENTS | | | | |
|-----------------------|-----------------|----------------------|---|-------------------------------------|
| Examiner Initials | Document Number | Kind Code (if known) | Name of Patentee or Applicant of Cited Document | Issue/Publication Date (MM-DD-YYYY) |
| | 3,752,886 | | Munder <i>et al.</i> | 08-14-1973 |
| | 4,159,988 | | Eibl <i>et al.</i> | 07-03-1979 |
| | 4,163,748 | | Eibl <i>et al.</i> | 08-07-1979 |
| | 4,382,035 | | Eibl | 05-03-1983 |
| | 4,734,225 | | Eibl | 03-29-1988 |
| | 4,804,789 | | Eibl | 02-14-1989 |
| | 4,920,016 | | Allen <i>et al.</i> | 04-24-1990 |
| | 4,965,391 | | Counsell <i>et al.</i> | 10-23-1990 |
| | 4,983,397 | | Schroit <i>et al.</i> | 01-08-1991 |
| | 5,013,556 | | Woodle <i>et al.</i> | 05-07-1991 |
| | 5,436,234 | A | Eibl | //07-25-1995 |
| | 5,762,958 | | Mayhew <i>et al.</i> | 06-09-1998 |
| | 5,932,242 | | Franklin <i>et al.</i> | 08-03-1999 |
| | 5,942,246 | A | Mayhew <i>et al.</i> | 08-24-1999 |
| | 5,965,159 | | Mayhew <i>et al.</i> | 10-12-1999 |
| | 6,007,839 | | Mayhew <i>et al.</i> | 12-28-1999 |
| | 6,017,557 | | Franklin <i>et al.</i> | 01-25-2000 |
| | 6,180,137 | B1 | Mayhew <i>et al.</i> | 01-30-2001 |

| FOREIGN PATENT DOCUMENTS | | | | | |
|--------------------------|-----------------|----------------------|---------------|----------------------------------|--------------------|
| Examiner Initials | Document Number | Kind Code (if known) | Country | Date of Publication (MM-DD-YYYY) | Translation Yes No |
| | 61-22022 | A | Japan | 01-30-1986 | |
| | 072294 | | Japan | 07--1986 | |
| | 1,583,661 | | Great Britain | 01-28-1981 | |
| | 0,213,523 | B1 | Europe | 12-12-1990 | |
| | 4,132,345 | | DE | 04-01-1993 | |
| | 4,408,011 | | DE | 11-02-1995 | |
| | 93/04673 | | WIPO | 03-18-1993 | |
| | 93/08202 | | WIPO | 04-29-1993 | |

| | | |
|--------------------|--|-----------------|
| Examiner Signature | | Date Considered |
|--------------------|--|-----------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

| | | |
|--|----------------------------------|--|
| Substitute for forms 1449A/PTO & 1449B/PTO | ATTORNEY'S DKT NO. 033388-566 | CONTINUATION OF APPLICATION NO. 09/540,050 |
| FIRST INFORMATION DISCLOSURE STATEMENT BY APPLICANT | APPLICANT Imran AHMAD et al | |
| | FILING DATE August 26, 2003 | GROUP Unassigned |

| FOREIGN PATENT DOCUMENTS | | | | |
|---------------------------------|---|------|------------|--|
| | 94/27580 | WIPO | 12-08-1994 | |
| NON PATENT LITERATURE DOCUMENTS | | | | |
| Examiner Initials | Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | | | |
| | Baker <i>et al.</i> , "Inhibition of Chronic Relapsing Experimental Allergic Encephalomyelitis in the Mouse by the Alkyl-Lysophospholipid ET-18-OCH ₃ ," <i>Int. J. Immuno Pharm.</i> , 13(4):395 (1991). | | | |
| | Bazill <i>et al.</i> , "Role of Endocytosis in the Action of Ether Lipids on WEHI-3B, HL60, and FEDCP-Mix A4 Cells," <i>Cancer Res.</i> 50:7505 (1990). | | | |
| | Berdel, "Membrane-interactive lipids as experimental anticancer drugs," <i>Br. J. Cancer</i> 64:208 (1991). | | | |
| | Berdel, "Ether Lipids and Derivatives as Investigational Anticancer Drugs," <i>Onkologie</i> 13:245 (1990). | | | |
| | Bhatia <i>et al.</i> , "Sterospecific Synthesis of Antitumor Active Thioether PAF Analogs," <i>Lipids</i> 26(12):1424 (1991). | | | |
| | Blume <i>et al.</i> , "Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times," <i>Biochim. Biophys. Acta.</i> , 1149:180-184 (1993). | | | |
| | Daicho <i>et al.</i> , "Effects of alkyl glycosides incorporated into liposomes prepared from synthetic amphiphiles on their tissue distribution in Ehrlich solid tumor-bearing mice," <i>BBA</i> , 1107:61 (1992). | | | |
| | Darnell <i>et al.</i> , <i>Molecular Cell Biology</i> , pp. 573-575 (1986), Scientific American Books, Inc., New York. | | | |
| | Deamer and Uster, "Liposome Preparation: Methods and Mechanisms," <i>Liposomes</i> , pp. 27-52 (1983), M. Ostro, ed., Marcel Dekker, Inc., New York. | | | |
| | Dietzfelbinger <i>et al.</i> , "Removal of Breast Cancer Cells from Bone Marrow by In Vitro Purging with Ether Lipids and Cryopreservation," <i>Cancer Research</i> , 53:3747 (1993). | | | |
| | Dive <i>et al.</i> , "Multiparametric Flow Cytometry of the Modulation of Tumor Cell Membrane Permeability by Developmental Antitumor Ether Lipid SRI 62-834 in EMT6 Mouse Mammary Tumor and HL-60 Human Promyelocytic Leukemia Cells," <i>Cancer Research</i> , 51:799 (1991). | | | |
| | Gabizon <i>et al.</i> , "Prolongation of Circulation Time of Doxorubicin Encapsulated in Liposomes Containing a Polyethylene Glycol-Derivatized Phospholipid: Pharmacokinetic Studies in Rodents and Dogs," <i>Pharm. Research</i> , 10(5):703 (1993). | | | |

| | | |
|--------------------|--|-----------------|
| Examiner Signature | | Date Considered |
|--------------------|--|-----------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

| | | |
|--|----------------------------------|--|
| Substitute for forms 1449A/PTO & 1449B/PTO | ATTORNEY'S DKT NO. 033388-566 | CONTINUATION OF APPLICATION NO. 09/540,050 |
| FIRST INFORMATION DISCLOSURE STATEMENT BY APPLICANT | APPLICANT Imran AHMAD et al | |
| | FILING DATE August 26, 2003 | GROUP Unassigned |

| NON PATENT LITERATURE DOCUMENTS | |
|--|---|
| Examiner Initials | Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. |
| | Kaufmann-Kolle <i>et al.</i> , "Liposomal Hexadecylphosphocholine (HEPC): In Vitro and In Vivo Application," <i>Chemical Abstracts</i> , (4), 10.08. |
| | Kucera <i>et al.</i> , "Novel Membrane-Interactive Ether Lipid Analogs That Inhibit Infectious HIV-1 Production and Induce Defective Virus Formation," <i>AIDS Research & Human Retroviruses</i> , 6(4):491 (1990). |
| | Layton <i>et al.</i> , "The Interaction of Liposomes with Cells: The Relation of Cell Specific Toxicity to Lipid Composition," <i>Eur. J. Cancer</i> , 16:64 (1980). |
| | Lewis <i>et al.</i> , "The Mesomorphic Phase Behavior of Lipid Bilayers," <i>The Structure of Biological Membranes</i> , pp. 73-155 at pp. 123-126 (1992), P. Yeagle, ed., CRC Press, Inc., Boca Raton, Fl. |
| | Mende <i>et al.</i> , "Effect of ET-18-OCH ₃ /Cholesterol Liposomes on the Membrane Potential of Isolated Endothelial Cells." <i>Pharmazie</i> , 44(2) (1989) |
| | Muschiol <i>et al.</i> , "Alkyl Phosphocholine: Toxicity and Anticancer Properties," <i>Lipids</i> , 22(11):930 (1987). |
| | Nairn, <i>Reington's Pharmaceutical Science</i> , pp. 1492-1517 (1985), A. Gennaro, ed., Mack Publishing Co., Easton, PA. |
| | Park <i>et al.</i> , "Some negatively charged phospholipid derivatives prolong the liposome circulation in vivo," <i>Biochim. Biophys. Acta.</i> , 1108:257 (1992). |
| | Powis <i>et al.</i> , "Selective Inhibition of Phosphatidylinositol Phospholipase C by Cytotoxic Ether Lipid Analogues," <i>Cancer Research</i> , 52:2835 (1992) |
| | Powis <i>et al.</i> , "The Cell Membrane and Cell Signals as Targets in Cancer Chemotherapy," <i>Cancer Research</i> , 50:2203 (1990). |
| | Reed <i>et al.</i> , "Antineoplastic Ether-linked Phospholipid induces differentiation of acute myelogenous leukemic KG-1 cells into macrophase-like cells," <i>Life Sci.</i> , 49:1221 (1991). |
| | Runge <i>et al.</i> , "Destruction of Human Solid Tumors by Alkyl Lysophospholipids." <i>JNCI</i> , 64(6):1301 (1980). |
| | Tritton <i>et al.</i> , "How to Kill Cancer Cells: Membranes and Cell Signaling as Targets in Cancer Chemotherapy," <i>Cancer Cells</i> , 2(4):95 (1990). |
| | Workman, "Antitumor Ether Lipids: Endocytosis as a Determinant of Cellular Sensitivity," <i>Cancer Cells</i> , 3(8):315 (1991). |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

SHEET 4 OF 4

| | | |
|--|---------------------------------------|--|
| Substitute for forms 1449A/PTO & 1449B/PTO | ATTORNEY'S DKT NO. 033388-566 | CONTINUATION OF APPLICATION NO. 09/540,050 |
| FIRST INFORMATION DISCLOSURE STATEMENT BY APPLICANT | APPLICANT Imran AHMAD et al | |
| | FILING DATE August 26, 2003 | GROUP Unassigned |

| NON PATENT LITERATURE DOCUMENTS | |
|---------------------------------|---|
| Examiner Initials | Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. |
| | Workman <i>et al.</i> , "Plastelet-activating factor (PAF) antagonist WEB 2086 does not modulate the cytotoxicity of PAF or antitumour alkyl lysophospholipids ET-18-O-Methyl and SRIU 62-834 in HL-60 promyelocytic leukaemia cells," <i>Biochem. Pharmacol.</i> , 41(2):319 (1991). |
| | Zeisig <i>et al.</i> , "Antineoplastic activity <i>in vitro</i> of free and liposomal alkylphosphocholines," <i>Anti-Cancer Drugs</i> , 4:57 (1993). |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.